Massimo Serra

11.8k total citations
188 papers, 8.6k citations indexed

About

Massimo Serra is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Massimo Serra has authored 188 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Molecular Biology, 87 papers in Pulmonary and Respiratory Medicine and 59 papers in Oncology. Recurrent topics in Massimo Serra's work include Sarcoma Diagnosis and Treatment (83 papers), Bone Tumor Diagnosis and Treatments (20 papers) and Cancer Genomics and Diagnostics (18 papers). Massimo Serra is often cited by papers focused on Sarcoma Diagnosis and Treatment (83 papers), Bone Tumor Diagnosis and Treatments (20 papers) and Cancer Genomics and Diagnostics (18 papers). Massimo Serra collaborates with scholars based in Italy, United States and Netherlands. Massimo Serra's co-authors include Katia Scotlandi, Piero Picci, Maria Cristina Manara, Claudia Maria Hattinger, Stefania Benini, Nicola Baldini, Pier‐Luigi Lollini, Daniela Maurici, Stefano Ferrari and Pancras C.W. Hogendoorn and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Massimo Serra

186 papers receiving 8.4k citations

Peers

Countries citing papers authored by Massimo Serra

Since Specialization

Citations

This map shows the geographic impact of Massimo Serra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Serra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Serra more than expected).

Fields of papers citing papers by Massimo Serra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Massimo Serra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Serra. The network helps show where Massimo Serra may publish in the future.

Co-authorship network of co-authors of Massimo Serra

This figure shows the co-authorship network connecting the top 25 collaborators of Massimo Serra. A scholar is included among the top collaborators of Massimo Serra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Massimo Serra. Massimo Serra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II study in pediatric and AYA patients with non-metastatic high-grade extremity osteosarcoma with a risk-adapted strategy based on P-glycoprotein (ISG/OS-2): A correlative study on tumour immune microenvironment. 2024 ·Journal of Clinical Oncology ·Emanuela Palmerini, Maria Rosaria Sapienza, Stefano Pileri, Alberto Righi, Antonina Parafioriti, (unknown), Claudio Agostinelli, Cristina Meazza, Virginia Ferraresi, Sebastian Dorin Asaftei, Luca Coccoli, Angela Tamburini, Marco Gambarotti, Massimo Serra, Davide María Donati, Franca Fagioli, Marilena Cesari, Katia Scotlandi, Maria Antonella Laginestra, Toni Ibrahim	1
2	Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma 2023 ·International Journal of Molecular Sciences ·Claudia Maria Hattinger, Iris C. Salaroglio, (unknown), Martina Godel, (unknown), Joanna Kopecka, Katia Scotlandi, Toni Ibrahim, Chiara Riganti, Massimo Serra	8
3	Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not? 2021 ·Cells ·Massimo Serra, Claudia Maria Hattinger, Michela Pasello, (unknown), (unknown), Chiara Riganti, Maria Cristina Manara	14
4	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts 2019 ·Cancer Letters ·Elena Gazzano, Ilaria Buondonno, Alessandro Marengo, Barbara Rolando, Konstantin Chegaev, Joanna Kopecka, Simona Saponara, Matteo Sorge, Claudia Maria Hattinger, Alberto Gasco, Roberta Fruttero, Mara Brancaccio, Massimo Serra, Barbara Stella, Elias Fattal, Silvia Arpicco, Chiara Riganti	54
5	PCN470 EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE MANAGEMENT OF PANCREATIC CANCER 2019 ·Value in Health ·Fernando Rivera, F. P. Antia, Teresa Macarulla, M. A. Mangues, Andrés Muñoz, (unknown), Massimo Serra	1
6	Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma 2018 ·International Journal of Molecular Sciences ·Elisa Martella, Claudia Ferroni, Andrea Guerrini, Marco Ballestri, Marta Columbaro, Spartaco Santi, Giovanna Sotgiu, Massimo Serra, Davide María Donati, Enrico Lucarelli, Greta Varchi, Serena Duchi	42
7	Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice 2018 ·Cancer Medicine ·Maria Eugénia Marques Da Costa, Estelle Daudigeos‐Dubus, Anne Gomez‐Brouchet, Olivia Bawa, Valérie Rouffiac, Massimo Serra, Katia Scotlandi, Conceição Santos, Birgit Geoerger, Nathalie Gaspar	12
8	Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma 2016 ·Molecular Cancer Therapeutics ·Ilaria Buondonno, Elena Gazzano, Sae Rin Jean, Valentina Audrito, Joanna Kopecka, Marilù Fanelli, Iris C. Salaroglio, Costanzo Costamagna, Ilaria Roato, Eleonora Mungo, Claudia Maria Hattinger, Silvia Deaglio, Shana O. Kelley, Massimo Serra, Chiara Riganti	83
9	Advances in emerging drugs for osteosarcoma 2015 ·Expert Opinion on Emerging Drugs ·Claudia Maria Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Stefano Ferrari, Piero Picci, Massimo Serra	77
10	An update on chemotherapy for osteosarcoma 2015 ·Expert Opinion on Pharmacotherapy ·Stefano Ferrari, Massimo Serra	179
11	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas 2014 ·BMC Cancer ·Clara Guerzoni, Stefano Amatori, Luca Giorgi, Maria Cristina Manara, Lorena Landuzzi, Pier‐Luigi Lollini, (unknown), (unknown), Marco Manfrini, L Pratelli, Massimo Serra, Piero Picci, Mauro Magnani, Vieri Fusi, Mirco Fanelli, Katia Scotlandi	16
12	Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents 2011 ·Clinical Cancer Research ·Emilie P. Buddingh, Marieke L. Kuijjer, R.A.J. Duim, Horst Bürger, Konstantin Agelopoulos, Ola Myklebost, Massimo Serra, Fredrik Mertens, Pancras C.W. Hogendoorn, Arjan C. Lankester, Anne‐Marie Cleton‐Jansen	376
13	Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines 2011 ·Molecular BioSystems ·A. C. SAU, Giuseppe Filomeni, Silvia Pezzola, Simona D’Aguanno, (unknown), Andrea Urbani, Massimo Serra, Michela Pasello, Piero Picci, Giorgio Federici, Anna Maria Caccuri	60
14	Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of Outcome 2009 ·Journal of Clinical Oncology ·Katia Scotlandi, Daniel Remondini, Gastone Castellani, Maria Cristina Manara, (unknown), (unknown), Mirko Francesconi, Mario Mercuri, Anna Maria Caccuri, Massimo Serra, Sakari Knuutila, Piero Picci	102
15	Prognostic Value of CCN3 in Osteosarcoma 2008 ·Clinical Cancer Research ·Bernard Perbal, Monia Zuntini, Diana Zambelli, Massimo Serra, Marika Sciandra, (unknown), Enrico Lucarelli, Piero Picci, Katia Scotlandi	49
16	Overcoming Glutathione S -Transferase P1–Related Cisplatin Resistance in Osteosarcoma 2008 ·Cancer Research ·Michela Pasello, Francesca Michelacci, Isabella Scionti, Claudia Maria Hattinger, Monia Zuntini, Anna Maria Caccuri, Katia Scotlandi, Piero Picci, Massimo Serra	105
17	Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma 2008 ·Annals of Oncology ·Isabella Scionti, Francesca Michelacci, Michela Pasello, Claudia Maria Hattinger, Marco Alberghini, Maria Cristina Manara, G. Bacci, Stefano Ferrari, Katia Scotlandi, Piero Picci, Massimo Serra	48
18	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling 2007 ·Cancer Research ·(unknown), Maria Cristina Manara, Cinzia Zucchini, Paola De Sanctis, Monia Zuntini, Luisa Valvassori, Massimo Serra, Martina Olivero, Maria Flavia Di Renzo, Mario P. Colombo, Piero Picci, Katia Scotlandi	75
19	The Expression of ccn3(nov) Gene in Musculoskeletal Tumors 2002 ·American Journal Of Pathology ·Maria Cristina Manara, Bernard Perbal, Stefania Benini, Rosaria Strammiello, Vanessa Cerisano, Stefania Perdichizzi, Massimo Serra, Annalisa Astolfi, Franco Bertoni, Jennifer Alami, Herman Yeger, Piero Picci, Katia Scotlandi	94
20	EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. 1994 ·Journal of Clinical Investigation ·Marco Giovannini, Jaclyn A. Biegel, Massimo Serra, (unknown), Yau‐Huei Wei, Lynn M. Nycum, B S Emanuel, Gerald A. Evans	116

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact